176 related articles for article (PubMed ID: 18556602)
1. Screening experiments and the use of fractional factorial designs in behavioral intervention research.
Nair V; Strecher V; Fagerlin A; Ubel P; Resnicow K; Murphy S; Little R; Chakraborty B; Zhang A
Am J Public Health; 2008 Aug; 98(8):1354-9. PubMed ID: 18556602
[TBL] [Abstract][Full Text] [Related]
2. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
3. Developing multicomponent interventions using fractional factorial designs.
Chakraborty B; Collins LM; Strecher VJ; Murphy SA
Stat Med; 2009 Sep; 28(21):2687-708. PubMed ID: 19575485
[TBL] [Abstract][Full Text] [Related]
4. Measuring illness representations in breast cancer survivors (BCS) prescribed tamoxifen: Modification and validation of the Revised Illness Perceptions Questionnaire (IPQ-BCS).
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Psychol Health; 2017 Apr; 32(4):439-458. PubMed ID: 28052692
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate.
Cunningham H
BMJ; 1996 Aug; 313(7055):494. PubMed ID: 8776338
[No Abstract] [Full Text] [Related]
6. New findings about endocrine therapy for breast cancer.
Davidson NE; Visvanathan K; Emens L
Breast; 2003 Dec; 12(6):368-72. PubMed ID: 14659107
[TBL] [Abstract][Full Text] [Related]
7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
8. [Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial].
Noël G; Mezziou M; Mazeron JJ
Cancer Radiother; 1999; 3(6):524-5. PubMed ID: 10630169
[No Abstract] [Full Text] [Related]
9. An examination of effect estimation in factorial and standardly-tailored designs.
Allore HG; Murphy TE
Clin Trials; 2008; 5(2):121-30. PubMed ID: 18375650
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and contralateral breast cancer.
O'Regan R; Jordan VC; Gradishar WJ
J Am Coll Surg; 1999 Jun; 188(6):678-83. PubMed ID: 10359362
[No Abstract] [Full Text] [Related]
11. Comparing two web-based smoking cessation programs: randomized controlled trial.
McKay HG; Danaher BG; Seeley JR; Lichtenstein E; Gau JM
J Med Internet Res; 2008 Nov; 10(5):e40. PubMed ID: 19017582
[TBL] [Abstract][Full Text] [Related]
12. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Winquist E; Bramwell V; Vandenberg T
J Clin Oncol; 2002 Sep; 20(17):3748-9; author reply 3749-50. PubMed ID: 12202679
[No Abstract] [Full Text] [Related]
13. A strategy for optimizing and evaluating behavioral interventions.
Collins LM; Murphy SA; Nair VN; Strecher VJ
Ann Behav Med; 2005 Aug; 30(1):65-73. PubMed ID: 16097907
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
15. [Tamoxifen--"golden standard" in the treatment of patients with early breast cancer].
Semiglazov VF; Kostetskaia TV
Vopr Onkol; 2001; 47(1):108-12. PubMed ID: 11317528
[No Abstract] [Full Text] [Related]
16. Computer modeling is no substitute for randomized clinical trials for decision making in early breast cancer hormonal therapy.
Vakaet LA
J Clin Oncol; 2005 Nov; 23(33):8543-4; author reply 8546-7. PubMed ID: 16293887
[No Abstract] [Full Text] [Related]
17. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
19. Choices and challenges in endocrine treatment for breast cancer.
Murta EF; Nomelini RS
Int J Clin Pract; 2007 Dec; 61(12):1962-4. PubMed ID: 17997799
[No Abstract] [Full Text] [Related]
20. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
